Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

Histopathology

Volumn 55, Issue 1, 2009, Pages 10-19

  Amatya, Vishwa Jeet ^c   Takeshima, Yukio ^a   Kohno, Hidekazu ^a   Kushitani, Kei ^a   Yamada, Taketo ^b   Morimoto, Chikao ^c   Inai, Kouki ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Caveolin 1; Differential diagnosis; Epithelioidmesothelioma; Immunohistochemistry; Lungadenocarcinoma

Indexed keywords

CALRETININ; CAVEOLIN 1; MONOCLONAL ANTIBODY D2-40; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; CAVEOLIN 1; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 68049123584     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03322.x     Document Type: Article

References (34)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N. Engl. J. Med. 2005 353 1591 1603.
2. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod. Pathol. 2005 18 105 110.
3. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn. Cytopathol. 2005 32 160 166.
4. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod. Pathol. 2007 20 248 255.
5. Mimura T, Ito A, Sakuma T et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007 109 933 938.
6. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005 36 372 380.
7. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv. Anat. Pathol. 2006 13 316 329.
8. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod. Pathol. 2006 19 34 48.
9. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum. Pathol. 2007 38 1 16.
10. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol. Int. 2007 57 190 199.
11. Comin CE, Dini S, Novelli L, Santi R, Asirelli G, Messerini L. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am. J. Surg. Pathol. 2006 30 463 469.
12. Soini Y, Kinnula V, Kahlos K, Paakko P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J. Clin. Pathol. 2006 59 250 254.
13. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathology & genetics. Tumours of the lung, pleura, thymus and heart. Lyon, France : IARC Press, 2004.
14. Glenney JR Jr., Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl Acad. Sci. USA 1992 89 10517 10521.
15. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 1992 68 673 682.
16. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008 27 715 735.
17. Quest A, Gutierrez-Pajares JL, Torres V. Caveolin-1, an ambiguous partner in cell signaling and cancer. J. Cell Mol. Med. 2008 12 1130 1150.
18. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arterioscler. Thromb. Vasc. Biol. 2003 23 1161 1168.
19. Rajamannan NM, Springett MJ, Pederson LG, Carmichael SW. Localization of caveolin 1 in aortic valve endothelial cells using antigen retrieval. J. Histochem. Cytochem. 2002 50 617 628.
20. Smart EJ, Ying YS, Anderson RG. Hormonal regulation of caveolae internalization. J. Cell Biol. 1995 131 929 938.
21. Hardin CD, Vallejo J. Caveolins in vascular smooth muscle: form organizing function. Cardiovasc. Res. 2006 69 808 815.
22. Ohnuma K, Yamochi T, Uchiyama M et al. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol. Cell. Biol. 2005 25 7743 7757.
23. Newman GR, Campbell L, von Ruhland C, Jasani B, Gumbleton M. Caveolin and its cellular and subcellular immunolocalisation in lung alveolar epithelium: implications for alveolar epithelial type I cell function. Cell Tissue Res. 1999 295 111 120.
24. von Ruhland CJ, Campbell L, Gumbleton M, Jasani B, Newman GR. Immunolocalization of caveolin-1 in rat and human mesothelium. J. Histochem. Cytochem. 2004 52 1415 1425.
25. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008 59 105 110.
26. Belanger MM, Roussel E, Couet J. Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest 2004 125 106S.
27. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003 27 1031 1051.
28. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol. Int. 2005 55 83 86.
29. Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn. Cytopathol. 2006 34 801 806.
30. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am. J. Surg. Pathol. 2003 27 150 158.
31. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 2000 24 598 606.
32. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum. Pathol. 2001 32 529 536.
33. Shijubo N, Honda Y, Fujishima T et al. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur. Respir. J. 1995 8 403 406.
34. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br. J. Cancer 2003 88 1229 1233.